• Capricor Therapeutics (NASDAQ:CAPR) Lifted to Buy at Zacks Investment Research

    Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a research report sent to …

    Read More
  • 0 0